349 related articles for article (PubMed ID: 17931986)
1. Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2.
Duncan JS; Litchfield DW
Biochim Biophys Acta; 2008 Jan; 1784(1):33-47. PubMed ID: 17931986
[TBL] [Abstract][Full Text] [Related]
2. [Casein kinase 2, the versatile regulator of cell survival].
Volodina IuL; Shtil' AA
Mol Biol (Mosk); 2012; 46(3):423-33. PubMed ID: 22888632
[TBL] [Abstract][Full Text] [Related]
3. Casein Kinase II: an attractive target for anti-cancer drug design.
Hanif IM; Hanif IM; Shazib MA; Ahmad KA; Pervaiz S
Int J Biochem Cell Biol; 2010 Oct; 42(10):1602-5. PubMed ID: 20558317
[TBL] [Abstract][Full Text] [Related]
4. New protein kinase CK2 inhibitors: jumping out of the catalytic box.
Prudent R; Cochet C
Chem Biol; 2009 Feb; 16(2):112-20. PubMed ID: 19246001
[TBL] [Abstract][Full Text] [Related]
5. Casein Kinase II (CK2) as a Therapeutic Target for Hematological Malignancies.
Gowda C; Sachdev M; Muthusami S; Kapadia M; Petrovic-Dovat L; Hartman M; Ding Y; Song C; Payne JL; Tan BH; Dovat S
Curr Pharm Des; 2017; 23(1):95-107. PubMed ID: 27719640
[TBL] [Abstract][Full Text] [Related]
6. Chemical proteomics and functional proteomics strategies for protein kinase inhibitor validation and protein kinase substrate identification: applications to protein kinase CK2.
Gyenis L; Turowec JP; Bretner M; Litchfield DW
Biochim Biophys Acta; 2013 Jul; 1834(7):1352-8. PubMed ID: 23416530
[TBL] [Abstract][Full Text] [Related]
7. An unbiased evaluation of CK2 inhibitors by chemoproteomics: characterization of inhibitor effects on CK2 and identification of novel inhibitor targets.
Duncan JS; Gyenis L; Lenehan J; Bretner M; Graves LM; Haystead TA; Litchfield DW
Mol Cell Proteomics; 2008 Jun; 7(6):1077-88. PubMed ID: 18258654
[TBL] [Abstract][Full Text] [Related]
8. A CK2-dependent mechanism for degradation of the PML tumor suppressor.
Scaglioni PP; Yung TM; Cai LF; Erdjument-Bromage H; Kaufman AJ; Singh B; Teruya-Feldstein J; Tempst P; Pandolfi PP
Cell; 2006 Jul; 126(2):269-83. PubMed ID: 16873060
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic targeting of CK2 in acute and chronic leukemias.
Buontempo F; McCubrey JA; Orsini E; Ruzzene M; Cappellini A; Lonetti A; Evangelisti C; Chiarini F; Evangelisti C; Barata JT; Martelli AM
Leukemia; 2018 Jan; 32(1):1-10. PubMed ID: 28951560
[TBL] [Abstract][Full Text] [Related]
10. Chemically induced degradation of CK2 by proteolysis targeting chimeras based on a ubiquitin-proteasome pathway.
Chen H; Chen F; Liu N; Wang X; Gou S
Bioorg Chem; 2018 Dec; 81():536-544. PubMed ID: 30245235
[TBL] [Abstract][Full Text] [Related]
11. Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells.
Romieu-Mourez R; Landesman-Bollag E; Seldin DC; Sonenshein GE
Cancer Res; 2002 Nov; 62(22):6770-8. PubMed ID: 12438279
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of 4,5,6,7-tetrahalogeno-1H-isoindole-1,3(2H)-diones as inhibitors of human protein kinase CK2.
Golub AG; Yakovenko OY; Prykhod'ko AO; Lukashov SS; Bdzhola VG; Yarmoluk SM
Biochim Biophys Acta; 2008 Jan; 1784(1):143-9. PubMed ID: 18021749
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways.
Piazza F; Manni S; Ruzzene M; Pinna LA; Gurrieri C; Semenzato G
Leukemia; 2012 Jun; 26(6):1174-9. PubMed ID: 22289987
[TBL] [Abstract][Full Text] [Related]
14. Order or chaos? An evaluation of the regulation of protein kinase CK2.
Olsten ME; Litchfield DW
Biochem Cell Biol; 2004 Dec; 82(6):681-93. PubMed ID: 15674436
[TBL] [Abstract][Full Text] [Related]
15. Targeting CK2-driven non-oncogene addiction in B-cell tumors.
Mandato E; Manni S; Zaffino F; Semenzato G; Piazza F
Oncogene; 2016 Nov; 35(47):6045-6052. PubMed ID: 27041560
[TBL] [Abstract][Full Text] [Related]
16. Roles of IKK kinases and protein kinase CK2 in activation of nuclear factor-kappaB in breast cancer.
Romieu-Mourez R; Landesman-Bollag E; Seldin DC; Traish AM; Mercurio F; Sonenshein GE
Cancer Res; 2001 May; 61(9):3810-8. PubMed ID: 11325857
[TBL] [Abstract][Full Text] [Related]
17. Protein kinase CK2 in health and disease: CK2: a key player in cancer biology.
Trembley JH; Wang G; Unger G; Slaton J; Ahmed K
Cell Mol Life Sci; 2009 Jun; 66(11-12):1858-67. PubMed ID: 19387548
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase CK2 in health and disease: CK2 and its role in Wnt and NF-kappaB signaling: linking development and cancer.
Dominguez I; Sonenshein GE; Seldin DC
Cell Mol Life Sci; 2009 Jun; 66(11-12):1850-7. PubMed ID: 19387549
[TBL] [Abstract][Full Text] [Related]
19. Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2.
Cozza G; Mazzorana M; Papinutto E; Bain J; Elliott M; di Maira G; Gianoncelli A; Pagano MA; Sarno S; Ruzzene M; Battistutta R; Meggio F; Moro S; Zagotto G; Pinna LA
Biochem J; 2009 Jul; 421(3):387-95. PubMed ID: 19432557
[TBL] [Abstract][Full Text] [Related]
20. Cellular regulators of protein kinase CK2.
Montenarh M
Cell Tissue Res; 2010 Nov; 342(2):139-46. PubMed ID: 20976471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
